ES2539503T3 - Anticuerpos que se unen a TGF-alfa y Epiregulina - Google Patents

Anticuerpos que se unen a TGF-alfa y Epiregulina Download PDF

Info

Publication number
ES2539503T3
ES2539503T3 ES12712049.1T ES12712049T ES2539503T3 ES 2539503 T3 ES2539503 T3 ES 2539503T3 ES 12712049 T ES12712049 T ES 12712049T ES 2539503 T3 ES2539503 T3 ES 2539503T3
Authority
ES
Spain
Prior art keywords
antibody
seq
alpha
amino acid
tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12712049.1T
Other languages
English (en)
Spanish (es)
Inventor
Catherine Brautigam Beidler
Josef George Heuer
Ramona Judita Petrovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2539503T3 publication Critical patent/ES2539503T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12712049.1T 2011-04-06 2012-03-28 Anticuerpos que se unen a TGF-alfa y Epiregulina Active ES2539503T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472338P 2011-04-06 2011-04-06
US201161472338P 2011-04-06
PCT/US2012/030802 WO2012138510A1 (en) 2011-04-06 2012-03-28 Antibodies that bind tgf-alpha and epiregulin

Publications (1)

Publication Number Publication Date
ES2539503T3 true ES2539503T3 (es) 2015-07-01

Family

ID=45929050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12712049.1T Active ES2539503T3 (es) 2011-04-06 2012-03-28 Anticuerpos que se unen a TGF-alfa y Epiregulina

Country Status (26)

Country Link
US (1) US8613921B2 (enrdf_load_stackoverflow)
EP (1) EP2694547B1 (enrdf_load_stackoverflow)
JP (1) JP2014515743A (enrdf_load_stackoverflow)
KR (1) KR101581517B1 (enrdf_load_stackoverflow)
CN (1) CN103459423B (enrdf_load_stackoverflow)
AR (2) AR085484A1 (enrdf_load_stackoverflow)
AU (1) AU2012240508B2 (enrdf_load_stackoverflow)
BR (1) BR112013023513A2 (enrdf_load_stackoverflow)
CA (1) CA2832256C (enrdf_load_stackoverflow)
CY (1) CY1116332T1 (enrdf_load_stackoverflow)
DK (1) DK2694547T3 (enrdf_load_stackoverflow)
EA (1) EA024921B1 (enrdf_load_stackoverflow)
ES (1) ES2539503T3 (enrdf_load_stackoverflow)
HR (1) HRP20150468T1 (enrdf_load_stackoverflow)
IL (1) IL228101A0 (enrdf_load_stackoverflow)
ME (1) ME02063B (enrdf_load_stackoverflow)
MX (1) MX2013011596A (enrdf_load_stackoverflow)
PL (1) PL2694547T3 (enrdf_load_stackoverflow)
PT (1) PT2694547E (enrdf_load_stackoverflow)
RS (1) RS54000B1 (enrdf_load_stackoverflow)
SG (1) SG193452A1 (enrdf_load_stackoverflow)
SI (1) SI2694547T1 (enrdf_load_stackoverflow)
TW (1) TWI454481B (enrdf_load_stackoverflow)
UA (1) UA110051C2 (enrdf_load_stackoverflow)
WO (1) WO2012138510A1 (enrdf_load_stackoverflow)
ZA (1) ZA201306813B (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合TGF-α及表皮調節素(EPIREGULIN)之抗體於治療疼痛之用途
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물
TWI859538B (zh) 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190858A (en) * 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
EP2087113A2 (en) 2006-10-11 2009-08-12 Fusion Antibodies Limited Combination therapy
MX2009003738A (es) 2006-10-12 2009-07-17 Forerunner Pharma Res Co Ltd Diagnóstico y tratamiento de cáncer usando anticuerpo anti-ereg.
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
US20120141501A1 (en) * 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component

Also Published As

Publication number Publication date
EP2694547B1 (en) 2015-03-18
CN103459423B (zh) 2016-03-02
WO2012138510A1 (en) 2012-10-11
KR101581517B1 (ko) 2015-12-30
ME02063B (me) 2015-05-20
KR20130133274A (ko) 2013-12-06
DK2694547T3 (en) 2015-04-27
EA201370196A1 (ru) 2014-02-28
IL228101A0 (en) 2013-09-30
EA024921B1 (ru) 2016-11-30
TW201300414A (zh) 2013-01-01
ZA201306813B (en) 2015-04-29
HK1190410A1 (en) 2014-07-04
JP2014515743A (ja) 2014-07-03
RS54000B1 (en) 2015-10-30
AU2012240508A1 (en) 2013-08-29
TWI454481B (zh) 2014-10-01
AU2012240508B2 (en) 2014-10-23
SI2694547T1 (sl) 2015-05-29
CA2832256C (en) 2016-02-09
US8613921B2 (en) 2013-12-24
CY1116332T1 (el) 2017-02-08
PL2694547T3 (pl) 2015-08-31
AR085484A1 (es) 2013-10-02
CN103459423A (zh) 2013-12-18
SG193452A1 (en) 2013-10-30
NZ614198A (en) 2015-09-25
PT2694547E (pt) 2015-06-01
UA110051C2 (uk) 2015-11-10
US20120258109A1 (en) 2012-10-11
MX2013011596A (es) 2013-12-09
EP2694547A1 (en) 2014-02-12
AR123912A2 (es) 2023-01-25
BR112013023513A2 (pt) 2016-11-22
CA2832256A1 (en) 2012-10-11
HRP20150468T1 (hr) 2015-06-05

Similar Documents

Publication Publication Date Title
US10913793B2 (en) DNA molecules encoding anti-IL-33 antibodies
ES2951648T3 (es) Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
ES2904586T3 (es) Anticuerpos anti-PD-1
KR102031020B1 (ko) 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
ES2780392T3 (es) Anticuerpos humanos contra Fel d1 y métodos de uso de los mismos
ES2539503T3 (es) Anticuerpos que se unen a TGF-alfa y Epiregulina
US9695241B2 (en) Ang2 antibodies
JP7558306B2 (ja) 疼痛の治療における使用のためのTGF-α及びエピレグリンに結合する抗体
JP2022513671A (ja) Cd40抗体医薬品組成物およびその使用
CA3229503A1 (en) Pharmaceutical composition containing fusion protein
CN115666643A (zh) 用于治疗异位性皮肤炎的抗il-36r抗体
NZ614198B2 (en) Antibodies that bind tgf-alpha and epiregulin
HK1190410B (en) Antibodies that bind tgf-alpha and epiregulin
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
CN119548621A (zh) 抗igf-1r抗体或其抗原结合部分在减重中的应用
HK40005780B (en) Anti-il-33 antibodies and uses thereof
HK40005780A (en) Anti-il-33 antibodies and uses thereof